2025.12.05 (금)

  • 맑음속초3.1℃
  • 맑음-0.3℃
  • 맑음철원-2.3℃
  • 맑음동두천-1.5℃
  • 맑음파주-1.3℃
  • 맑음대관령-4.5℃
  • 맑음춘천0.5℃
  • 구름많음백령도4.1℃
  • 맑음북강릉2.5℃
  • 맑음강릉3.8℃
  • 맑음동해4.0℃
  • 맑음서울0.9℃
  • 맑음인천0.9℃
  • 맑음원주-1.5℃
  • 구름조금울릉도3.1℃
  • 맑음수원1.3℃
  • 맑음영월-0.8℃
  • 맑음충주-0.7℃
  • 맑음서산2.7℃
  • 맑음울진4.0℃
  • 맑음청주1.8℃
  • 맑음대전1.6℃
  • 맑음추풍령0.5℃
  • 맑음안동1.4℃
  • 맑음상주1.3℃
  • 맑음포항4.6℃
  • 맑음군산4.1℃
  • 맑음대구3.6℃
  • 맑음전주2.6℃
  • 맑음울산3.8℃
  • 맑음창원4.6℃
  • 맑음광주3.9℃
  • 맑음부산5.0℃
  • 맑음통영5.8℃
  • 맑음목포3.8℃
  • 맑음여수5.9℃
  • 구름많음흑산도4.8℃
  • 맑음완도5.0℃
  • 맑음고창3.0℃
  • 맑음순천2.8℃
  • 맑음홍성(예)2.5℃
  • 맑음0.4℃
  • 구름많음제주7.4℃
  • 구름조금고산6.9℃
  • 맑음성산6.1℃
  • 구름많음서귀포9.6℃
  • 맑음진주5.5℃
  • 구름조금강화-1.2℃
  • 맑음양평0.1℃
  • 맑음이천0.1℃
  • 맑음인제-0.7℃
  • 맑음홍천-1.8℃
  • 맑음태백-1.6℃
  • 맑음정선군-1.1℃
  • 맑음제천-1.7℃
  • 맑음보은0.4℃
  • 맑음천안1.4℃
  • 맑음보령2.7℃
  • 맑음부여3.3℃
  • 맑음금산1.1℃
  • 맑음1.5℃
  • 맑음부안3.6℃
  • 맑음임실1.7℃
  • 맑음정읍3.1℃
  • 맑음남원3.0℃
  • 맑음장수-0.2℃
  • 맑음고창군3.0℃
  • 맑음영광군2.9℃
  • 맑음김해시4.8℃
  • 맑음순창군3.1℃
  • 맑음북창원5.3℃
  • 맑음양산시5.9℃
  • 맑음보성군5.2℃
  • 맑음강진군4.8℃
  • 맑음장흥4.4℃
  • 맑음해남4.9℃
  • 맑음고흥4.4℃
  • 맑음의령군4.3℃
  • 맑음함양군3.8℃
  • 맑음광양시5.8℃
  • 맑음진도군3.9℃
  • 맑음봉화-0.5℃
  • 맑음영주-0.3℃
  • 맑음문경0.3℃
  • 맑음청송군1.1℃
  • 맑음영덕2.9℃
  • 맑음의성2.8℃
  • 맑음구미2.4℃
  • 맑음영천2.9℃
  • 맑음경주시3.5℃
  • 맑음거창2.2℃
  • 맑음합천5.4℃
  • 맑음밀양4.6℃
  • 맑음산청3.7℃
  • 맑음거제2.3℃
  • 맑음남해3.5℃
  • 맑음5.4℃
기상청 제공
Shoppy 로고
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
  • 해당된 기사를 공유합니다

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Last trading day of Vifor registered shares: 22 December 2022
Delisting date of Vifor registered shares: 23 December 2022

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a “Vifor Share”). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court.

Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:

Last trading day: 22 December 2022

Delisting date: 23 December 2022

As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD 179.25 in cash per cancelled Vifor Share. The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

Forward-Looking Statements

This announcement may contain statements that constitute forward-looking statements. The words “anticipate”, “believe”, “expect”, “estimate”, “aim”, “project”, “forecast”, “estimate”, “risk”, “likely”, “intend”, “outlook”, “should”, “could”, “would”, “may”, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, “target”, “plan” and other similar expressions are intended to identify forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.

This announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005876/en/

언론연락처: CSL Vifor Media Contact Thomas Hutter Mobile: +41 79 957 96 73 Investor Contact CSL Limited Steve McKeon Associate Director, Investor Relations Mobile +61 402 231 696 Switzerland / Europe Martin Meier-Pfister (IRF) + 41 432 448 140

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기